Trial Profile
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Foslinanib (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors TaiRx
- 04 Dec 2023 Planned End Date changed from 1 Nov 2023 to 31 Dec 2024.
- 04 Dec 2023 Planned primary completion date changed from 1 Nov 2022 to 30 Sep 2024.
- 04 Dec 2023 Status changed from recruiting to active, no longer recruiting.